Our previous works have demonstrated that FGFR1 tumor expression was an independent prognostic factor of time to progression and overall survival in patients treated with radiotherapy for glioblastoma [6] and that inhibiting FGFR [15], and more specifically FGFR1 [7], increased the radiosensitivity of glioblastoma differentiated cells. Here, FGFR1 is linked to neoplasm.